Jinis Co., Ltd.

Hea Guk Cho

Seong Tshool Hong

Hyeon Jin Kim

Hea Jong Chung

Min Kyu Joo

Jinny Hong

Jae Gak Yu

Heui Kwan Lee

Disclosed are a sensitizing composition for thermal cancer therapy using electromagnetic waves and a method of treating cancer using the composition. The sensitizing composition includes a metal ion, a metal ion-bound material, metal ion-noncovalently bound apotransferrin (transferrin), or a metal ion-noncovalently bound apotransferrin derivative. The sensitizing composition enables selective delivery of the metal ion to tumorous tissue when administered in vivo, and thus the generation of heat in tumorous tissue in which the metal ion accumulates is increased upon thermal cancer therapy using electromagnetic waves, thereby maximizing efficacy of thermal cancer therapy using electromagnetic waves in treating cancer. Thermal therapy using the sensitizing composition effectively treats cancer without pain or side effects and is thus expected to be widely useful in anticancer treatment as monotherapy, and/or in combination with chemotherapy, radiation therapy, or a combination thereof, ultimately increases the potential to cure cancer.

Sensitizing composition using electromagnetic waves for thermal therapy of cancers, and cancer therapy using same

Targeting-enhanced anticancer nanoparticles and preparation methods for the nanoparticles are provided. In particular, this invention provides targeting-enhanced anticancer nanoparticles comprising non-covalently bound anticancer drugs, serum albumins as the nanoparticle base material, and porphyrin compounds as tumor-targeting moieties. The targeting-enhanced anticancer nanoparticles described in the present invention are characterized by non-covalently bound constituents: anticancer drugs, serum albumin as the nanoparticle base material, and porphyrin compounds as tumor-targeting moieties, thus preventing common toxic side effects, enhancing the structural stability of nanoparticles, and enhancing tumor targeting by treatment with electromagnetic waves due to the activity of porphyrin, without structural and functional changes. Taken together, the present invention provides a chemotherapeutic method that maximizes drug delivery/tumor targeting and is expected to be a successful therapy for both early-stage and late-stage cancer.

Targeting-enhanced anticancer nanoparticles and preparation methods of same

This invention encompasses targeting-enhanced anticancer nanoparticles and preparation methods for the same. In particular, this invention provides targeting-enhanced anticancer nanoparticles comprising non-covalently bound anticancer drugs, serum albumins as the nanoparticle base material, and porphyrin compounds as tumor-targeting moieties. The targeting-enhanced anticancer nanoparticles described in the present invention are characterized by non-covalently bound constituents: anticancer drugs, serum albumin as the nanoparticle base material, and porphyrin compounds as tumor-targeting moieties, thus preventing common toxic side effects, enhancing the structural stability of nanoparticles, and enhancing tumor targeting by treatment with electromagnetic waves due to the activity of porphyrin, without structural and functional changes. Taken together, the present invention provides a chemotherapeutic method that maximizes drug delivery/tumor targeting and is expected to be a successful therapy for both early-stage and late-stage cancer.

Growing community of inventors

Gwangju, South Korea

Hea Guk Cho